Biocryst

CSL links drug to rare disease benefits, plans global filings

Phase 3 data on CSL’s garadacimab in a rare disease suggest the antibody may have an edge over Takeda’s Takhzyro in terms of efficacy and convenience.

Nick Paul Taylor Feb 27, 2023 10:15am

BioCryst hits another hurdle, delays trial after pipeline culls

Feb 23, 2023 11:33am

BioCryst scraps $200M offering after seeing share price slide

Aug 11, 2021 7:35am

BioCryst starts COVID-19 trial of broad-spectrum antiviral

Apr 10, 2020 7:55am

BioCryst says oral drug works for HAE attacks

Sep 4, 2018 10:15am

BioCryst stockholders call off merger with Idera Pharmaceuticals

Jul 11, 2018 10:20am